Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

Preliminary data from an ongoing Phase 2 trial evaluating satraplatin plus Taxol(R) (paclitaxel) in the first-line treatment of patients with advanced non-small cell lung cancer were also published in the ASCO educational book (Shipley, D. et al. Phase II trial of satraplatin and paclitaxel in the first-line treatment of advanced non-small cell lung cancer). Data from 24 patients were available for analysis; a total of approximately 40 patients are expected to be enrolled in the study. This preliminary analysis showed that satraplatin plus Taxol appears to have activity in this treatment setting. In an effort to reduce myelosuppression in the study, the satraplatin dose has been lowered to 70 mg/m2 from 80 mg/m2. The study continues to enroll and follow patients.

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration. Satraplatin is an oral compound that clinical trial patients are able to take at home. Satraplatin is not currently approved by the FDA in the United States, by the EMEA in the European Union or any other regulatory authority and no conclusions can or should be drawn regarding its safety and efficacy.

A Phase 3 registrational trial, called SPARC, is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone- refractory prostate cancer whose prior chemotherapy has failed. Data from the trial on progression-free survival and on safety have been presented at recent medical conferences.

GPC Biotech has a co-development and license agreement with Pharmion GmbH, a wholly owned subsidiary of Pharmion Corporation, under which Pharmion has been granted exclusive commercialization rights to satraplatin for Europe and certain other territories.
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Study ... Finds -, PRINCETON, ... of,vesicoureteral reflux (VUR) in children, reduced the incidence of recurrent,urinary tract infections ... in the July issue of the Journal of,Laparoendoscopic & Advanced Surgical Techniques. ...
... Online on Aug. 5 in Nature Journal, CLEVELAND, ... region within high density lipoprotein (HDL), the major,carrier of ... inhibiting the body,s ability to fight cholesterol buildup. ... M.D., Ph.D., Head of,the Section of Preventive Cardiology and ...
Cached Medicine Technology:DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux 2DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux 3DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux 4Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol 2Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol 3
(Date:10/20/2014)... Punzoné , the first line of ultra-premium organic ... to celebrate this month. October marks Italian Heritage Month – ... of Americans of Italian heritage and Italians in America. October ... its favorite Italian cocktails and encourages everyone to enjoy its ... it is only in a glass. , Punzoné continues ...
(Date:10/19/2014)... 20, 2014 Hastings and Hastings, a ... of service throughout the greater Phoenix area and across ... with regard to catastrophic automobile accidents. Statistics have indicated ... and throughout Arizona. As such, Hastings and Hastings has ... representation for those who have been injured through no ...
(Date:10/19/2014)... Dr. Babatunde Osotimehin, Executive Director of ... a ceasefire agreement that is expected to lead to ... were kidnapped from the north-eastern Nigerian town of Chibok—the ... enough, and it is high time they are returned ... , "We owe it to these girls to positively ...
(Date:10/19/2014)... Recently, Top10BestSEOHosting.com has unveiled its newest hosting ranking ... are the best VPS hosting suppliers in the ... method of partitioning a physical server computer into ... and capabilities of running on someone’s own dedicated ... attention to VPS products and related suppliers. ...
(Date:10/19/2014)... Visual Impact Frequency Training - ... released to the public generating a frenzied buzz ... fitness community. The commotion surrounding the program's launch ... prompting an investigative review. , "Many gym-goers are ... commonly known as a training 'plateau' where they ...
Breaking Medicine News(10 mins):Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... Nov. 7 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... that it will release its financial results for,the quarter ... after,the close of the U.S. financial markets. CryoCor ... at 5:00 p.m. ET /,2:00 p.m. PT on November ...
... With Business Objectives, Watson ... Survey Finds, WASHINGTON, Nov. 7 With continuing ... offer financial,incentives to reward workers who adopt healthy lifestyles, ... global consulting firm, and the,National Business Group on Health, ...
... 7 A cholesterol-lowering drug appears to disrupt sleep ... Heart Associations Scientific Sessions 2007. , The findings are ... and may have adverse health consequences, such as promoting ... lead author of the study and an associate professor ...
... Nov. 7 Exposing estrogen-sensitive breast cancer cells to ... sewer and industrial waste causes the cells to multiply, ... at the annual meeting of the American Public Health ... will be presented at a special session on Contaminants ...
... Director, Campaign for,Tobacco-Free Kids, WASHINGTON, Nov. 7 ... Philip Morris and R.J. Reynolds tobacco companies have,again ... by defeating a,ballot initiative to increase Oregon,s cigarette ... companies will profit by selling more cigarettes,while Oregonians ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today ... Operating Officer, will present at the JMP Securities,Healthcare ... 2007 at 2:30 p.m.,Eastern Time. To access ... visit the Investor Relations section of Genomic Health,s,website ...
Cached Medicine News:Health News:CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 3Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 4Health News:Cholesterol-lowering drug linked to sleep disruptions 2Health News:Extracts of catfish caught in polluted waters cause breast cancer cells to multiply 2Health News:Tobacco Industry Puts Profits Before Kids in Defeating Oregon Ballot Initiative 2Health News:Genomic Health to Present at JMP Securities Healthcare Focus Conference 2
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. High volume/low pressure cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. S...
Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Graduat...
Medicine Products: